Update on the treatment of Behcet's syndrome


ESATOĞLU S. N. , HATEMİ G.

INTERNAL AND EMERGENCY MEDICINE, cilt.14, ss.661-675, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 14 Konu: 5
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/s11739-019-02035-1
  • Dergi Adı: INTERNAL AND EMERGENCY MEDICINE
  • Sayfa Sayıları: ss.661-675

Özet

Behcet's syndrome (BS) is a complex disease that shows important heterogeneity in clinical findings and physiopathology. Its treatment can be problematic as BS manifestations in different organs may respond differently to the same drug. The cornerstone of therapy for inducing remission is corticosteroids whereas immunomodulatory and immunosuppressive agents such as colchicine, azathioprine, cyclosporine-A, interferon-alpha, and cyclophosphamide are used as steroid-sparing agents and to prevent further relapses. However, a considerable number of patients continue to have mucocutaneous lesions despite therapy, and some patients require more aggressive treatment for refractory major organ involvement. Tumor necrosis factor alpha inhibitors, especially infliximab and adalimumab, are increasingly used for various refractory BS manifestations despite the lack of controlled studies. In this review, we aim to focus on both the traditional and new treatment modalities for BS, with more emphasis on recent data on newer agents.